同和药业(300636) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 220,746,478.69, representing a 22.79% increase compared to CNY 179,771,415.86 in the same period last year[5] - Net profit attributable to shareholders was CNY 33,096,474.74, up 23.36% from CNY 26,828,215.64 year-on-year[5] - The total operating revenue for the first quarter of 2023 was CNY 220,746,478.69, an increase of 22.8% compared to CNY 179,771,415.86 in the same period last year[23] - The net profit attributable to the parent company for the first quarter of 2023 was CNY 33,096,474.74, compared to CNY 26,828,215.64 in the previous year, representing a growth of 23.4%[24] - The total comprehensive income for the first quarter of 2023 was CNY 33,096,474.74, an increase from CNY 26,828,215.64 in the same period last year, representing a growth of approximately 23.5%[25] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 11.59% to CNY 85,264,632.48 from CNY 96,438,592.52 in the previous year[10] - The company's cash and cash equivalents decreased by 40.15% to CNY 84,960,709.82 from CNY 141,963,915.05 at the beginning of the period[7] - The net cash flow from financing activities increased significantly by 260.43% to CNY 79,153,361.13 from a negative CNY 49,338,103.33 in the previous year[11] - Net cash flow from operating activities was CNY 85,264,632.48, down from CNY 96,438,592.52 in the previous year, indicating a decrease of approximately 11.1%[28] - The company reported a decrease in cash and cash equivalents by CNY 47,370,255.23, compared to a decrease of CNY 81,640,864.77 in the previous year[28] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,333,114,239.79, a 3.29% increase from CNY 2,258,855,478.13 at the end of the previous year[5] - The total liabilities increased to CNY 972,001,271.81 from CNY 939,186,880.03, indicating a rise of 3.5%[22] - Accounts receivable increased to CNY 117,611,560.19 from CNY 87,829,525.65, marking a growth of 33.9%[21] - Inventory decreased to CNY 467,125,058.50 from CNY 497,358,472.51, a reduction of 6.1%[21] Research and Development - Research and development expenses increased by 67.09% to CNY 19,210,151.13 compared to CNY 11,496,727.71 in the same period last year[9] - The company's R&D expenses for the first quarter of 2023 were CNY 19,210,151.13, up from CNY 11,496,727.71, reflecting a significant increase of 67.5%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,625[13] - The largest shareholder, Mr. Pang Zhengwei, holds 18.85% of shares, totaling 66,009,954 shares, with 15,750,000 shares pledged[13] - The second largest shareholder, Fenglong Industrial Co., Ltd., holds 15.85% of shares, totaling 55,511,352 shares[13] - The company’s major shareholders, including Mr. Pang and Mr. Liang, are considered acting in concert, jointly controlling the company[14] Capital Projects and Investments - The company has completed the first phase of its new plant project, which includes four workshops that are now in trial production[17] - The company is expanding its second plant with new construction and renovation projects, which commenced in July 2022[17] - The company has completed the application for a specific issuance of A-shares, which has been approved by the Shenzhen Stock Exchange and the China Securities Regulatory Commission[18] Stock and Incentives - The total number of restricted shares at the beginning of the period was 60,606,349, with 77,813 shares released during the period[16] - The company has a stock incentive plan with a total of 5,362,650 shares subject to restrictions[16] - The company has a total of 8,800,000 shares held by Guotai Junan's flexible allocation mixed fund[14] - The company has a total of 3,000,000 shares held by Agricultural Bank of China’s innovative growth mixed fund[14] Operating Costs - The total operating costs for the first quarter of 2023 were CNY 178,963,287.50, up from CNY 149,238,774.57, reflecting a year-over-year increase of 19.9%[24] - The cash inflow from sales of goods and services was CNY 176,923,633.02, slightly down from CNY 176,974,887.71 in the previous year, showing a marginal decline of about 0.03%[28] - The total cash outflow from operating activities was CNY 107,476,010.99, which increased from CNY 102,135,796.85 in the previous year, indicating a rise of approximately 5.3%[28] Other Information - The company did not report any new product launches or technological advancements during this quarter[29]